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THE INFLUENCE OF ANTIRETROVIRAL AND ANTITUBERCULOSIS AGENTS ON
THE BIOCHEMICAL AND HISTOPATHOLOGICAL INDICES OF LIVER
FUNCTION IN RATS
 O. O. Shevchuk, K. A. Posokhova, O. M. Oleshchuk, T. V. Datsko
I. YA. HORBACHEVSKYTERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. Standard antituberculosis treatment and highly active antiretroviral therapy are frequently
associated with hepatotoxicity leading to drugs discontinuation.
Objective. This study aimed to assess the signs of hepatotoxicity in albino rats in case of simultaneous
usage of tuberculostatics (TBS) and antiretroviral agents (ART).
Methods. Healthy rats were divided in 4 groups: 1st control group; 2nd group was given tuberculostatics
(isoniazid – 50 mg/kg, rifampicin – 50 mg/kg and pyrazinamide – 1500 mg/kg); 3rd group was given ART (efavi-
renz – 150 mg/kg and stavudine – 5 mg/kg); 4th group was given TBS and ART. The animals were sacrificed
painlessly on the 29th day; blood and liver samples were obtained. The main biochemical and histopathological
indices were determined.
Conclusions. Comparing with control group, repeated usage of TBS caused the prominent liver injury with
cytolysis and cholestasis signs, decreasing of CYP3A and CYP2E1 isozymes activity and dysfunction of protein
synthesis by the liver. ART (efavirenz and stavudine) caused the elevation of transaminases activity with the
increase of serum bilirubin level at the background of increase in cytochrome 450 isoforms 3A and 2E1 activities
and total serum protein. The antiretroviral agents in case of simultaneous administration with the antituberculosis
drugs diminished the hepatotoxic effects of first-line drugs for tuberculosis treatment which was confirmed by
the study of liver histopathology. Such results of our experimental study give encouragement for further detailed
clinical research of drug-drug interaction of both pharmacological groups due to the rising cases of HIV-associated
tuberculosis in the whole world.
KEY WORDS: Isoniazid, rifampicin, pyrazinamide, efavirenz, stavudine, liver, cytochrome P450.
Introduction
The global burden of tuberculosis (TB) is enor-
mous today (Fig. 1) [1]. The overlapping epidemio-
logy of HIV and TB as simultaneous infections has
had catastrophic consequences. The interaction
between these diseases is bidirectional. HIV infection
increases the risk of both primary and reactivated
TB [2], and this risk increases markedly with advan-
cing of HIV disease. The case fatality rates of HIV-
associated TB are high; the estimated aggregate
case fatality rate of HIV-infected TB is about 40 %,
and may be over 50 % in many developing co-
untries [3].
When choosing therapy for patients with HIV and
TB, drug–drug interactions should be carefully
considered. Rifampicin is an upregulator of CYP450
enzymes that catalyzes the metabolism of a number
of other drugs, including the NNRTI (Non-nucleoside
reverse-transcriptase inhibitors) efavirenz (EFV).
Concomitant Highly Active Antiretroviral Therapy
(HAART) during TB therapy is complicated by high
pill burden, concerns about drug-drug interactions,
paradoxical immune reconstitution reactions and the
main problem is overlapping drug toxicities (table 1)
[4, 5, 6].
The treatment of tuberculosis is complicated by
drug-induced hepatotoxicity, with reported rates
ranging widely, from approximately 3 to 25 %, depen-
ding on the hepatotoxicity definitions, the regimens,
the methodologies, and the study populations [7].
Hepatotoxicity is a relatively common adverse
drug reaction leading to treatment interruptions in
HIV patients, observed with different drug combina-
tions [8]. Currently, the top priority for World Health
Organization (WHO) is to increase coverage of ART
for HIV-positive TB patients towards the 100 %
target [1].
Isonazid (isonicotinylhydrazine, INH) in treat-
ment of all types of TB is associated with mild to
moderate elevation of liver enzymes and sometimes
with severe hepatotoxicity. Rifampicin (RFP), which
is commonly used in combination with INH, was
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reported to result in higher rate of liver injury,
especially with the simultaneous administration of
pyrazinamide (PZA). Thus in this study we
investigate the influence of first-line antituberculosis
and antiretroviral drugs alone and in combination on
main functions of the liver.
Methods
INH, RFP and PZA were secured from
“Borshchahivskiy CPP” (Ukraine). Antiretroviral
agents – EFV and d4T (Aurobindo Pharma Ltd.,
India) were kindly provided by State Institution
“Ukrainian Center for AIDS Prevention of the Ministry
of Health of Ukraine”.
Animals and study design
The white inbred rats (200±20 g, n=24) were
taken from TSMU vivarium. Animals were randomly
distributed into 4 groups (n=6): 1 – intact group; 2 –
rats which were treated with combination of
antituberculosis drugs isoniazid (50 mg/kg),
pyrazinamide (1500 mg/kg) and rifampicin (50 mg/
kg); 3 – rats which were treated with the components
of HAART: efavirenz (150 mg/kg) and stavudine
(d4T, 5 mg/kg); and 4 – rats for which both
antiretroviral and antituberculosis drugs in the
abovementioned doses were used. A suspension of
granulated tablets was introduced via the tube into
the rat stomach once a day during 28 days. Rats of
intact group were given equivalent quantity of distilled
water. The rats were weighted and sacrificed under
Ketamine hydrochloride general anesthesia on the
29th day. The blood and liver samples were taken
for investigation. All animals’ procedures were
performed according to the rules and requirements
of European Convention for the Protection of
Vertebrate Animals Used for Experimental and Other
Scientific Purposes and local Ethic Committee.
Biochemical analysis
Serum activities of aspartate aminotransferase
(AST) and alanine aminotransferase (ALT), alkaline
phosphatase, concentration of total bilirubin, serum
total protein, creatinine and urea were determined
Table 1. Overlapping or additive adverse drugs effects of antiretroviral and first-line
antituberculosis agents
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Fig. 1. Estimated TB incidence rates, 2012. Reproduced from World Health Organization. Global tuberculosis report 2013.
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using standard test kits «Lachema». Thiobarbituric
acid-reactive substances (TBARS), catalase activity
were determined as described earlier [9, 10]. Plasma
ceruloplasmin level was determined as well [11]. The
liver tissue was homogenized by using the homo-
genizer Silent Crusher S (Heidolph, Germany). The
concentrations of lipid hydroperoxides [12], TBARS,
superoxide dismutase (SOD) [13], catalase activity
and reduced glutathione level (G-SH) [14] were
analyzed in liver homogenates. p-hydroxylase
activity as a marker of CYP2E1 and N-demethylase
activity as a marker for cytochrome P450 – CYP3A
activity in rat hepatic microsomes were determined;
liver microsomes were prepared by differential ultra-
centrifugation [15]. We determined the content of
the active form of INH in serum of experimental
animals also [16].
Histopathological studies
Slices of the liver (from six animals of each
group) were fixed in 10 % formalin, and then Lilly-
fixator was applied. Samples were embedded in
paraffin; 5–6 m sections were routinely stained with
haematoxylin and eosin and observed using
microscope LOMO Biolam.
Statistical analysis
Results were presented as the mean ± standard
error of the mean (M±m) and analyzed by the Mann-
Whitney-test and ANOVA-test using Statsoft STATIS-
TICA 10 (at Systemic Statistical Analysis Department
of TSMU). A probability level of less than 0.05 was
considered as significant. The distribution of indices
was estimated using Shapiro-Wilk normality test.
Results
Combination of the most effective and common
antituberculosis agents has the most prominent
negative effect on liver function. We observed the
rising of liver transaminases levels and cholestatic
syndrome: increasing of ALT and AST activity by
163 and 118 %, respectively, increasing of alkaline
phosphatase and total bilirubin level – by 77 and
104 %, respectively, in comparison with intact control
(table 2). Also, there are some problems with liver
functions due to decreasing of total protein serum
level by 40 %.
The influence of antiretroviral agent on indices
of cytolysis and cholestasis was milder. We noted
the increase in ALT and AST activities by 42 and
45 % comparing with the control group rats (table 2).
The main positive findings of our study are that
the concomitant administration of EFV and d4T with
INH, RMP and PZA decreased the hepatotoxicity of
antituberculosis drugs (Figure 2). The group of rats
which received the treatment of all five drugs had
decreased levels of ALT, AST and alkaline phos-
phatase activity by 34, 36 and 27 %, respectively,
total bilirubin level was lower by 23 %, and total serum
protein level was higher by 95 % comparing with
rats which were treated with antituberculosis agents
alone. However, there was no full restoration of all
indices. It was noted that the ALT, AST and alkaline
phosphatase activities and total bilirubin levels were
still higher in rats treated with antituberculosis agents
Table 2. The changes of biochemical indices of serum in case of antiretroviral and antituberculosis
agents usage (M±m, n=6)
Index 
The group of 
animals ALT, 
mccat/l 
AST, 
mccat/l 
Alkaline 
phosphatase, 
mml/(l·hour) 
Total bilirubin, 
mcmol/l 
Total protein, 
g/l 
Control rats  0.85±0.03 1.15±0.07 1.86±0.08 2.38±0.10 60.82±1.88 
INH, RFP, PZA 2.24±0.08* 2.51±0.06* 2.38±0.17* 4.86±0.29* 36.88±0.76* 
EFV, d4T 1.21±0.04* 1.43±0.06* 2.07±0.04 3.23±0.05* 74.01±0.12* 
INH, RFP,  
PZA+EFV, d4T 1.48±0.04*
# 1.61±0.06*# 2.40±0.20*# 3.74±0.14*# 71.87±4.54* 
Notes. Statistical significance level is p<0.05 for this and for the following tables comparing with:
1. * – intact rats;
2. # – group of rats which received antituberculosis agents INH, RFP, PZA;
3. • – group of rats which received antiretroviral agents EFV, d4T.
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Fig. 2. The cytolysis and cholestasis indices in case of
antituberculosis and antiretroviral agents’ administration.
Notes: p<0.05 comparatively with * – intact rats, # – rats which
were treated with combination of antituberculosis drugs
isoniazid (INH, 50 mg/kg), pyrazinamide (PZA, 1500 mg/kg)
and rifampicin (RMP, 50 mg/kg).
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alone than in control rats by 73, 40, 29 and 57 %,
respectively.
The biochemical markers of intensive oxidative
stress were detected after administration of com-
bination of antituberculosis agents (Table 3). It was
observed that the levels of HPL and TBARS in liver
tissue increased by 86 and 144 % respectively;
TBARS in blood serum – by 99 % in comparison
with intact group on the 29th day. The decrease in
SOD activity (by 39 %) and catalase activity in liver
homogenates and blood serum – by 55% and 32.5%,
respectively, was observed. Simultaneously, the
levels of G-SH and CP were lower by 29 %, the
level of ceruloplasmin was higher by 19 %,
respectively, compared to control group.
Antiretroviral agents caused some lipoperoxi-
dation of cells membranes: HPL level in the liver
increased by 21 %, TBARS in the liver tissue and
serum – by 50 and 23 %, respectively, comparing
with control rats (table 3). As for indices of endogenic
antioxidant defense, SOD and catalase activity in
the liver were lower by 46 and 40 %, in the serum –
by 31 and 32 %, respectively, comparing with control
group. The G–SH was lower by 22 %, ceruloplasmin
level increased by 16 %.
The levels of primary and secondary products
of lipids membranes peroxidation were lower in the
group of rats which received combination of
antiretroviral and antituberculosis agents comparing
with the rats which were treated with antituberculosis
combination INH, RMP, PZA alone. For example,
HPL level was lower by 24 %, TBARS in liver tissue
and serum – by 32 and 30 %. As for activity of SOD
and catalase in the liver, they were higher by 20.8
and 21 %, respectively.
The antiretroviral agents EFV and d4T caused
the increase of N-demethylase and p-hydroxylase
activity by 34 and 26 %, respectively. Similarly,
antituberculosis drugs INH, RMP and  PZA caused
N-demethylase and p-hydroxylase activity decrease
by 54 and 33 %, respectively, all results comparing
with intact rats (Figure 3).
The level of serum free INH was lower by 18 %
in rats which received combined treatment of EFV,
d4T and INH, RMP, PZA, comparing with the group
of animals which were treated with antituberculosis
agents alone (table 4).
Histologic findings were done as described
below. We observed the lobular disarray, dilation of
central veins, and signs of fatty and hyaline-drops
protein dystrophy in case of treatment with antituber-
culosis drugs. All cells had different structure and
sizes. We found increased number of cells with
kariopicnosis, fragmentation and karyolysis (Fig. 4
(1)). ART had no the influence on lobular structure
of the liver (Fig. 4 (2)). However, we noticed the
hyperplasia of hepatocytes due to the enlargement
of homogenous cytoplasm and hyperplasia of
granulated nuclei. Cholestasis signs were not
Fig. 3. The influence of ART and antituberculosis agents on
N-demethylase and p-hydroxylase activity of l iver
microsomes.
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Table 3. The influence of antiretroviral and antituberculosis agents on prooxidant
and antioxidant homeostasis (M±m, n=6)
Notes. In this and all the following tables: statistical significance p<0.05 comparatively with:
1. * – control rats;
2. # – group of rats which received antituberculosis agents INH, RFP, PZA;
3. • – group of rats which received antiretroviral agents EFV, d4T.
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observed. In case of drug administration from both
pharmacological groups, we noticed the saved
lobular structure of the liver (Fig. 4 (3)). The struc-
ture of hepatic cells was normal; cytoplasm was
saturated and homogeneous in all cells of the liver
lobule. The histological structure of the liver was
improved comparing to the liver structure of the rats
which were treated with combination of anti-
tuberculosis drugs.
Discussion
At least one-third of the 34 million people living
with HIV worldwide are infected with latent TB.
Persons co-infected with TB and HIV are 21–34
times more likely to develop active TB disease than
persons without HIV. Coinfection with HIV leads to
difficulties in both the diagnosis and treatment of
tuberculosis. The problem of simultaneous admi-
nistration of antituberculosis and antiretroviral drugs
in patients with HIV-associated tuberculosis is
ambiguous due to overlapping side effect profiles of
drugs both pharmacological groups, the adherence
challenges of polypharmacy and their drug-drug
interaction especially on the stage of metabolism by
liver microsome enzymes. Today state-of-art in
combination of such drugs is described below. The
treatment of patients with TB and HIV should include
the first line drugs for TB treatment (common com-
bination of isoniazid, rifampicin, and pyrazinamide)
and NNRTI based antiretroviral therapy regimen, if
possible; efavirenz and rifampin are the preferred
components [18]. It is known that EVR is metabolized
by isoenzyme of CYP450 – CYP3A preferably and
by CYP2B and 2A also [6]. This NNRTI causes the
induction of CYP3A in the liver, but not in the intestine
[19]. Nucleoside reverse-transcriptase inhibitors
(NRTIs), like d4T, are metabolized by glucuronidation
pathway and don’t have any influence on CYP450
[20]. Concerning the antituberculosis drugs, RMP is
a potent inducer of CYP3A isoenzyme, as well as of
other P450 isoforms, more potent than rifapentine
and rifabutin [21]. PZA can induce CYP2E1 [22]. We
also know that hepatotoxicity of INH depends on
activity of this isoenzyme [23].
The SAPiT trial – an open-label randomized
controlled trial in Durban, South Africa to determine
optimal timing of ART initiation in relation to TB
treatment – showed that initiation of ART during
tuberculosis treatment in patients with sputum
smear positive for tuberculosis and HIV-infection,
reduced mortality by 56 % and was associated with
improved outcomes [17]. Our study reasserts the
results of this trial.
We can see the improving of all liver functions
due to the repeated administration of components
of ART, especially total serum protein level. Such
results are explained because of induction of
enzymes of the liver endoplasmic reticulum by EFV
[19]. The influence of antiretroviral agent on indices
of cytolysis and cholestasis was mild. The increase
in total bilirubin level was noted. We can explain this
by the fact that one of the mechanisms of EFV-
induced cholestasis is inhibition of bile acids transport
[24]. Our results are supported by the clinical data
of the similar studies which showed the absence of
risk of isoniazid–associated hepatitis in case of
concomitant HAART [25].
	



	 



	

	  !" #$ !%&
Notes. * – the significance level p<0.05 comparing with the rats which received antituberculosis drugs.
Table 4. The influence of antiretroviral and antituberculosis agents on serum isoniazid level in rats (M±m)
Fig. 4. Histopathological structure of rat liver in case of administration of antiretroviral and antituberculosis agents alone and
in combination: 1. Liver structure of rats which were treated with combination of PZA, INH and RMP. Haematoxylin and eosin
stain. 160; 2. Liver structure of rats which were treated with antiretroviral agents for 28 days. Haematoxylin and eosin stain.
160; 3. Liver structure of rats which received combination of antituberculosis and antiretroviral agents. Haematoxylin and
eosin stain. 160.
1     2         3
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Liver biopsy is the traditional gold standard to
ascertain the degree of liver injury. Our biochemical
results are confirmed by histological observations.
Functionally, the liver can be divided into three zones,
based upon oxygen supply. Zone 1 encircles the
portal tracts where the oxygenated blood from
hepatic arteries enters. Zone 3 is located around
central veins, where oxygenation is poor. Zone 2 is
located between the first two zones. The main mass
of CYP450 enzymes is located in zone 3 of hepatic
acinus [29]. Some studies showed increased activity
of CYP3A and CYP2E1 in case of isoniazid and
rifampicin administration [30]. That’s why the de-
creasing of activity of these isozymes can be
explained by higher hepatotoxicity of such dose of
PZA which was added to the combination of INH
and RMP. We can observe the necrosis of hepatic
cells in centrolobular part of liver lobule which is the
main cause of depression of such liver function as
detoxification. We can suggest that the decrease in
concentration of toxic metabolite of INH due to the
combination of RMP and EVF is the key factor in
decreasing of isoniazid hepatotoxicity, and the
absence of cases of liver toxicity during preventive
INH therapy with the HAART background [25, 31].
Possible mechanisms in decreasing the negative
influence of antituberculosis agents in case of their
combination with antiretroviral agents can be
explained by the fact that inducers of cytochrome
P450 enzymes stimulate synthetic and antitoxic liver
functions and can decrease the quantity of necrotic
hepatocytes [26]. Due to this we can see  improved
metabolism and detoxification processes due to the
stimulation of cytochrome P450 isozymes in case
of simultaneous usage of antituberculosis and
antiretroviral agents. Hepatotoxicity of INH is linked
to its metabolites - monoacetyl-hydrazine, hydrazine,
acetyl-isoniazid and others [27]. Isoniazid is meta-
bolized by genetically polymorphic arylamine N-
acetyltransferase type 2 (NAT2), and recent studies
showed that isoniazid concentrations may be more
toxic for slow acetylators after a standard therapeutic
dosing [28], because of relative overdosing and
higher concentration of INH toxic metabolites in the
blood. That’s why the increase in isonicotinyl
hydrazine metabolism can accompany the mitigation
of its hepatotoxic effects.
Conclusion
The present study showed that the combination
of first-line antituberculosis drugs (isoniazid, rifam-
picin and pyrazinamide) in case of their intragastric
administration during 28 days caused the prominent
liver injury with cytolysis and cholestasis signs,
decreasing of CYP3A and CYP2E1 isozymes activity
and dysfunction of protein synthesis by the liver.
Antiretroviral agents (efavirenz and stavudine),
after their administration into the stomach for 28 days,
caused the elevation of transaminases activity with
the increase of serum bilirubin level at the back-
ground of cytochrome 450 isoforms 3A and 2E1
activity rising and the increase of total serum protein.
The antiretroviral agents in case of simultaneous
administration with the antituberculosis drugs
diminished the hepatotoxic effects of the first-line
drugs for tuberculosis treatment. Such results of our
experimental study may facilitate the detailed clinical
research of drug-drug interaction from both pharma-
cological groups due to the rising cases of HIV-
associated tuberculosis in the whole world.
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